CCR5 et CXCR4 sont les corécepteurs d'entrée du VIH utilisés par le virus in vivo en plus du récepteur principal CD4 pour infecter les cellules. Au début et tout le long de l'infection, on retrouve chez les patients infectés par le VIH, des virions R5 utilisant le corécepteur CCR5 pour infecter les cellules. Dans les stades tardifs de l'infection et chez environ la moitié des personnes infectées par le VIH, on observe en plus de ces souches R5, l'apparition de souches X4, utilisant le corécepteur CXCR4 pour infecter les cellules. Cette apparition de souches X4 est un facteur d'aggravation de la maladie. Les causes de cette commutation de R5 vers X4 sont mal définies. Le but de mon travail de thèse a été de trouver de nouvelles stratégies thérapeutiques visant l'un ou l'autre de ces corécepteurs. La première partie de mon travail compare les deux isoformes de CXCR4 en tant que corécepteurs du VIH. Ces deux isoformes, CXCR4-A et CXCR4-B, diffèrent de 9 acides aminés en NH2 terminal suite à un épissage alternatif. Nous avons montré que l'isoforme CXCR4-B est la plus performante en tant que corécepteur du VIH mais que ces deux variants sont équivalents pour la migration vers leur ligand commun SDF-1. Ainsi, nous proposons qu'en ciblant exclusivement l'isoforme B qui est la plus favorable à l'infection, via par exemple des siRNA, il serait possible de limiter les infections par des souches X4 tout en gardant une partie des fonctions essentielles de ce récepteur dans l'organisme, assurées par l'isoforme A. Nos résultats suggèrent également que l'infection par des souches R5 augmente le ratio en ARNm CXCR4-B / CXCR4-A dans des PBMC, et que ce ratio est en partie responsable de la commutation de R5 vers X4 associée à une aggravation de la maladie. Cibler cette isoforme CXCR4-B pourrait donc se révéler bénéfique. La deuxième partie de cette thèse étudie la modulation de la fonction de corécepteur du VIH de CCR5 par S1P1, un autre membre de la famille des récepteurs couplés aux protéines G qui permet la remise en circulation des lymphocytes après leur séjour dans les organes lymphoïdes secondaires par chimiotactisme vers son ligand S1P, abondant dans le sang. Nous montrons que S1P1 interagit physiquement avec CCR5 et gêne l'entrée des virus R5 dans la cellule-hôte. A l'inverse, S1P1 active les étapes post-entrée du cycle viral, notamment l'expression génique virale. La résultante de ces effets opposés est une augmentation de la production virale par des cellules infectées in vitro. Ce projet a également montré que l'utilisation de FTY720, un antagoniste fonctionnel de S1P1, diminue l'infection de cellules dendritiques par des virus HIV-R5 in vitro, ainsi que la virémie dans un modèle de souris SCID infectées après reconstitution immunologique. La mise en évidence des interactions entre CCR5 et S1P1 ouvre donc des perspectives thérapeutiques. / CCR5 and CXCR4 are the two HIV entry coreceptors used by the virus in addition to the main receptor CD4 in vivo to infect cells. R5 virions, that use CCR5 as a coreceptor to infect cells, are detected in most HIV patients. At late stages of infection and in about half of HIV infected persons, there is an emergence of X4 virions that use CXCR4 as a coreceptor, in addition to R5 virions. This emergence is associated with an increase in disease progression. The reasons for this R5 to X4 switch are poorly understood. The goal of my PhD work was to find new therapeutic strategies that target these coreceptors.The first part of this work compares the two CXCR4 isoforms as HIV coreceptors. Those two isoforms, CXCR4-A and CXCR4-B, differ by 9 amino acids at their NH2 terminal extremity as a consequence of an alternative splicing. We have shown that CXCR4-B isoform is more efficient as an HIV coreceptor but that those two variants are equivalent in terms of chemotaxis toward their common ligand SDF-1. Thus, we propose that by targeting specifically the B isoform that supports infection, via siRNA by example, it is possible to limit X4 development while keeping essential functions of this receptor. Our results also suggest that R5 infection increases CXCR4-B / CXCR4-A mRNA ratio in PBMC and that this ratio is in part responsible for R5 to X4 switch. Thus, targeting CXCR4-B isoform could be beneficial.The second part of this PhD thesis studies the effect on CCR5 coreceptor function of S1P1, another G protein-coupled receptor that enables lymphocytes egress from lymph nodes by chemotaxis toward its ligand S1P that is abundant in blood. We have shown that S1P1 physically interacts with CCR5 and blocks R5 virus entry. On the other hand, S1P1 activates post-entry steps of the viral cycle, in particular gene expression. The resulting effect is an increase in viral production by infected cells in vitro. We also showed that the use of FTY720, a S1P1 functional antagonist, decreases dendritic cell infection by R5 viruses in vitro, and in vivo infection in a SCID mouse model. The emphasis of CCR5 and S1P1 interactions opens new therapeutic strategies.

Yes / Although the ability of bioactive lipid sphingosine-1-phosphate (S1P) to positively regulate anti-apoptotic/pro-survival responses by binding to S1P1 is well known, the molecular mechanisms remain unclear. Here we demonstrate that expression of S1P1 renders CCL39 lung fibroblasts resistant to apoptosis following growth factor withdrawal. Resistance to apoptosis was associated with attenuated accumulation of pro-apoptotic BH3-only protein Bim. However, although blockade of extracellular signal-regulated kinase (ERK) activation could reverse S1P1-mediated suppression of Bim accumulation, inhibition of caspase-3 cleavage was unaffected. Instead S1P1-mediated inhibition of caspase-3 cleavage was reversed by inhibition of phosphatidylinositol-3-kinase (PI3K) and protein kinase C (PKC), which had no effect on S1P1 regulation of Bim. However, S1P1 suppression of caspase-3 was associated with increased expression of anti-apoptotic protein Mcl-1, the expression of which was also reduced by inhibition of PI3K and PKC. A role for the induction of Mcl-1 in regulating endogenous S1P receptordependent pro-survival responses in human umbilical vein endothelial cells was confirmed using S1P receptor agonist FTY720- phosphate (FTY720P). FTY720P induced a transient accumulation of Mcl-1 that was associated with a delayed onset of caspase-3 cleavage following growth factor withdrawal, whereas Mcl-1 knockdown was sufficient to enhance caspase-3 cleavage even in the presence of FTY720P. Consistent with a pro-survival role of S1P1 in disease, analysis of tissue microarrays from ER þ breast cancer patients revealed a significant correlation between S1P1 expression and tumour cell survival. In these tumours, S1P1 expression and cancer cell survival were correlated with increased activation of ERK, but not the PI3K/PKB pathway. In summary, pro-survival/anti-apoptotic signalling from S1P1 is intimately linked to its ability to promote the accumulation of pro-survival protein Mcl-1 and downregulation of pro-apoptotic BH3-only protein Bim via distinct signalling pathways. However, the functional importance of each pathway is dependent on the specific cellular context. / Diabetes UK; British Heart Foundation

京都大学 / 0048 / 新制・論文博士 / 博士(医学) / 乙第13167号 / 論医博第2154号 / 新制||医||1029(附属図書館) / (主査)教授 宮本 享, 教授 小泉 昭夫, 教授 柳田 素子 / 学位規則第4条第2項該当 / Doctor of Medical Science / Kyoto University / DFAM

Submitted by Ana Paula Macedo (ensino@ioc.fiocruz.br) on 2013-10-03T12:26:40Z No. of bitstreams: 1 Carolina Valença Messias.pdf: 1326403 bytes, checksum: adde2666bf9c1e45634b4ea4926b6090 (MD5) / Made available in DSpace on 2013-10-03T12:26:40Z (GMT). No. of bitstreams: 1 Carolina Valença Messias.pdf: 1326403 bytes, checksum: adde2666bf9c1e45634b4ea4926b6090 (MD5) Previous issue date: 2012 / Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Rio de Janeiro, RJ, Brasil / A leucemia linfoblástica aguda de células T (LLA-T) e o linfoma linfoblástico de células T (LL-T) são proliferações malignas de precursores de células T em diferentes estágios de maturação. LLA-T e LL-T são considerados atualmente duas formas de uma mesma doença, a leucemia/linfoma linfoblástico de células T (LLL-T), por compartilharem características morfológicas, imunofenotípicas e genéticas. Como os blastos de LLL-T apresentam características similares às de timócitos normais, moléculas envolvidas na migração destas células podem também estar envolvidas na migração ou homing dos linfoblastos no curso da doença. Neste sentido, foi demonstrado recentemente que o receptor 1 de esfingosina-1-fosfato (S1P1) é essencial para a saída de timócitos do timo. No presente estudo, decidimos avaliar a expressão e o papel do S1P1 na migração de quatro linhagens celulares de LLA-T (HPB-ALL, MOLT-4, CEM e JURKAT) em resposta ao seu ligante fisiológico, a esfingosina-1-fosfato (S1P). Observamos que a linhagem HPB-ALL apresentou baixa expressão de RNAm de S1P1, enquanto MOLT-4 e JURKAT apresentaram uma expressão mediana e CEM apresentou altos níveis de expressão de RNAm para este receptor. Em ensaios funcionais de migração celular observamos que a capacidade migratória das linhagens frente a S1P foi diretamente relacionada ao nível de expressão gênica do receptor. A S1P induziu a migração das linhagens analisadas em diferentes concentrações até 100 nM, e inibiu a migração quando aplicada em altas concentrações (1000 nM). As respostas migratórias foram acompanhadas pela modulação do citoesqueleto de actina. Dependendo da concentração de S1P utilizada, observamos polimerização (menores concentrações) ou despolimerização (maiores concentrações) da actina. Além disso, o prétratamento das células com W146 (inibidor de S1P1) bloqueou a migração das linhagens frente à S1P em menores concentrações e induziu a migração frente à S1P em altas concentrações, sugerindo que a migração seja especificamente mediada por S1P1. Nossos resultados sugerem que as interações mediadas por S1P/S1P1 modulam a migração não apenas de precursores de células T normais, mas também de linfoblastos de LLL-T. Desta forma, a interação S1P/S1P1 pode ser considerada como alvo para possíveis estratégias terapêuticas frente a estas neoplasias. / T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (TLBL) are malignant proliferations of T cell precursors at different stages of normal development. T-ALL and T-LBL are presently believed to represent two different forms of a single disease, the T-cell lymphoblastic leukemia/lymphoma (T-LLL), as they share morphological, immunophenotypic and genetic features. As T-LLL lymphoblasts present similar characteristics of normal T cell precursors, molecules involved on the migration of these cells might also be associated with migration and homing of T-ALL/LBL. In this context, the sphingosine-1-phosfate receptor 1 (S1P1), has been described as essential for mouse thymocyte migration and thymic egress. Herein, we evaluated the expression and role of S1P1 in four T-ALL cell lines (HPBALL, MOLT-4, CEM e JURKAT) in response to its physiological ligand, the sphingosine-1-phophate (S1P). We observed that HPB-ALL cells presented low expression levels of S1P1 mRNA, whereas MOLT-4 and JURKAT had medium levels and CEM showed high levels of S1P1 expression. In functional migration assays, we observed that the migratory response of the cells towards S1P was directly related with their expression levels of the receptor. S1P induced the migration of the cell lines analyzed in different concentrations up to 100 nM and inhibited cell migration at higher concentrations (1000 nM). Moreover, migratory responses were accompanied by the modulation of actin cytoskeleton. Depending on S1P concentrations, we observed actin polymerization (lower concentrations) or depolymerization (higher concentrations). Pre-treatment of the cells with W146 (a S1P1 inhibitor) blocked S1Pinduced migration at lower concentrations but induced migration towards S1P at high concentrations, suggesting that the migration is specifically mediated by S1P1. Our results suggest that interactions mediated by S1P/S1P1 can modulate cell migration of T-LLL blasts similarly to their normal T cell precursor counterparts. Accordingly, immune intervention upon this ligand/receptor interaction may be envisioned as a potential therapeutic strategy for these malignancies.

L'activation dérégulée de lymphocytes T conduit à une réponse immune délétère envers les antigènes du soi. Malgré une utilisation croissante de doses élevées d'IVIg pour traiter les maladies auto-immunes, la compréhension des mécanismes sous-jacents aux bénéfices thérapeutiques demeure un enjeu majeur. En effet, les effets des IVIg restent inexplorés dans le cadre des maladies auto-immunes associées aux lymphocytes T. J'ai recherché les effets de doses élevées d'IVIg dans la polarisation des lymphocytes T en utilisant le modèle de l'encéphalomyélite auto-immune expérimentale (EAE), une maladie auto-immune associée aux lymphocytes T. Les IVIg inhibent la différenciation des lymphocytes T CD4+ naïfs en sous-populations effectrices (lymphocytes Th1 et Th17) et induisent, de manière concomitante, une prolifération des lymphocytes T Foxp3+. Les IVIg diminuent les effets délétères des lymphocytes T sur les tissus en diminuant l'expression du GM-CSF et de la podoplanine. En outre, les IVIg empêchent la dégénérescence neuronale en inhibant l'infiltrat en lymphocytes T CD4+ dans le système nerveux central (SNC). Ce mécanisme passe par une séquestration de ces lymphocytes dans les ganglions lymphatiques drainants à travers la voie de signalisation S1P-S1P1-mTor. De manière intéressante, et contrairement aux données actuelles, le récepteur inhibiteur FcγRIIB et la sialylation des IVIg ne sont pas indispensables pour la modulation des sous-populations de lymphocytes T CD4+ effecteurs et régulateurs induite par les IVIg. Ainsi, le bénéfice thérapeutique des IVIg dans le modèle de l'EAE implique un déséquilibre de la balance entre les lymphocytes Th17/Th1 et les lymphocytes Trég, au profit des lymphocytes Trég. Ces cellules diminuent l'expression de médiateurs favorisant l'apparition de l'encéphalomyélite et inhibent la migration des lymphocytes T vers l'organe cible.